Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Novartis puts a €2.7bn BET on MorphoSys
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
